1887

Journal of General Virology header logo

Volume 83, Issue 11

Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response Free

Abstract

Removal of the V1–V3 loops from IIIB gp120 results in a protein, PR12, with altered immunogenicity compared to the full-length protein. Polyclonal immune sera raised in rats using PR12 as immunogen recognizes envelope glycoproteins of clades A, B, C, E, F and G and can neutralize chimeric human immunodeficiency virus type 1 (HIV-1) HXB2 viruses expressing envelopes from primary HIV-1 clades B, C, E and F. These data suggest that the immune response to PR12 is directed toward conserved epitopes expressed by viral glycoproteins of diverse genotypes. Five monoclonal antibodies (mAb) derived from PR12-immunized rats were unable to neutralize virus infectivity; hence the epitopes responsible for the induction of this cross-clade neutralizing activity remain to be elucidated. However, PR12 immune sera were able to compete with the human neutralizing mAb 2G12 for gp120 binding, implying that this epitope may be immunogenic when expressed in the context of this truncated protein.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-11-2723
2002-11-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/11/0832723a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-11-2723&mimeType=html&fmt=ahah

References

  1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., Fenyo E.-M. 1990; Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 4:107–112
     [Google Scholar]
  2. Albert J., Bjorling E., Vongegerfelt A., Scarlatti G., Zhang Y. J., Fenyo E-M., Thorstensson R. 1993; Antigen-detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Research and Human Retroviruses 9:501–504
     [Google Scholar]
  3. Baba T. W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L. A., Posner M. R., Katinger H., Stiegler G., Bernacky B. J., Rizvi T. A., Schmidt R., Hill L. R., Keeling M. E., Lu Y., Wright J. E., Chou T.-C., Ruprecht R. M. 2000; Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus interaction. Nature Medicine 6:200–206
     [Google Scholar]
  4. Back N. K. T., Smith L., Dejog J. J. 1994; An N -glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199:431–443
     [Google Scholar]
  5. Berman P. W., Matthews T. J., Riddle L., Champe M., Hobbs M. R., Nakamura G. R., Mercer J., Eastman D. J. 1992; Antisera raised against gp120 from the MN isolate of HIV-1. Journal of Virology 66:4464–4469
     [Google Scholar]
  6. Binley J. M., Sanders R. W., Las B., Schuelke N., Master A., Guo Y., Fajumo F., Anselma D. J., Maddon P. J., Olson W. C., Moore J. P. 2000; A recombinant human immunodeficiency virus type I envelope glycoprotein complex stabilised by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. Journal of Virology 74:627–643
     [Google Scholar]
  7. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., Katinger H. 1994; Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein–Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Research and Human Retroviruses 10:359–369
     [Google Scholar]
  8. Burton D. R., Montefiori D. C. 1997; The antibody response in HIV-1 infection. AIDS 11: Supplement AS87–S98
     [Google Scholar]
  9. Burton D. R., Moore J. P. 1998; Why do we not have an HIV vaccine and how can we make one?. Nature Medicine 4:495–498
     [Google Scholar]
  10. Chackerian B., Rudensey L. M., Overbaugh J. 1997; Specific N -linked and O -linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus that evolve in the host alter recognition by neutralizing antibodies. Journal of Virology 71:7719–7727
     [Google Scholar]
  11. Chakrabarti B. K., Kong W.-P., Wu B.-Y., Yang Z.-Y., Friborg J., Ling X., King S. R., Montefiori D. C., Nable G. J. 2002; Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. Journal of Virology 76:5357–5368
     [Google Scholar]
  12. Connor R. I., Korber B. T. M., Graham B. S., Hahn B. H., Ho D. D., Walker B. D., Neuman A. U., Vermund S. H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kuntsman K. J., McDonald D., McWilliams N., Trkola A., Moore J. P., Wolinksky S. M. 1998; Immunological and virological analyses of persons infected by human immunodeficiency virus type I while participating in trials of recombinant gp120 subunit vaccines. Journal of Virology 72:1552–1576
     [Google Scholar]
  13. Cordell J., Moore J. P., Dean C. J., Klasse P. J., Weiss R. A., McKeating J. A. 1991; Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. Virology 185:72–79
     [Google Scholar]
  14. Fenouillet E., Blanes N., Benjouad A., Gluckman J. C. 1995; Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity. Clinical and Experimental Immunology 99:419–424
     [Google Scholar]
  15. Jeffs S. A., McKeating J., Lewis S., Craft H., Biram D., Stephens P. E., Brady R. L. 1996; Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. Journal of General Virology 77:1403–1410
     [Google Scholar]
  16. Jeffs S. A., Gorny M. K., Williams C., Revesz K., Volsky B., Burda S., Wang X.-H., Bandres J., Zolla-Pazner S., Holmes H. 2001; Characterisation of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1IIIB gp120. Immunology Letters 79:209–213
     [Google Scholar]
  17. LaCasse R. A., Follis K. E., Trahey M., Scarborough J. D., Littman D. R., Nunberg J. H. 1999; Fusion-competent vaccines: broad neutralisation of primary isolates of HIV. Science 283:357–362
     [Google Scholar]
  18. Lewis J., Balfe P., Arnold C., Kaye S., Tedder R. S., McKeating J. M. 1998; Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. Journal of Virology 72:8943–8951
     [Google Scholar]
  19. McKeating J. A., Cordell J., Dean C. J., Balfe P. 1992; Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191:732–742
     [Google Scholar]
  20. McKeating J. A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M., Bolmstedt A., Olofsson S., Wu Z., Pinter A., Dean C., Sodroski J., Weiss R. A. 1993; Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology 67:4932–4944
     [Google Scholar]
  21. McKeating J. A., Shotton C., Jeffs S., Palmer C., Hammond A., Lewis J., Oliver K., May J., Balfe P. 1996; Immunogenicity of full-length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. Immunology Letters 51:101–105
     [Google Scholar]
  22. Mascola J. R., Lewis M. G., Stiegler G., Harris D., VanCott T. C., Hayes D., Louder M. L., Brown C. R., Sapan C. V., Frankel S. S., Lu Y., Robb M. L., Katinger H., Birx D. L. 1999; Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology 73:4009–4018
     [Google Scholar]
  23. Mascola J. R., Stiegler G., VanCott T. C., Katinger H., Carpenter C. B., Hanson C. E., Beary H., Hayes D., Frankel S. S., Birx D. L., Lewis M. G. 2000; Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 6:207–210
     [Google Scholar]
  24. Montefiori D. C., Evans T. G. 1999; Towards an HIV type1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Research and Human Retroviruses 15:689–698
     [Google Scholar]
  25. Moore J. P., Sattentau Q., Wyatt R., Sodroski J. 1994; Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. Journal of Virology 68:469–484
     [Google Scholar]
  26. Moore J. P., Trkola A., Korber B., Boots L. J., Kessler J., McCutchan F. E., Mascola J., Ho D. D., Robinson J., Conley A. J. 1995; A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of Virology 69:122–30
     [Google Scholar]
  27. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., Katinger H. 1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67:6642–6647
     [Google Scholar]
  28. Nunberg J. 2002; Retraction (letter). Science 296:1025
     [Google Scholar]
  29. Nyambi P. N., Gorny M. K., Bastiani L., Van Der Groen G., Williams C., Zolla-Pazner S. 1998; Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. Journal of Virology 72:9384–9391
     [Google Scholar]
  30. Pollard S. R., Rosa M. D., Rosa J. J., Wiley D. C. 1992; Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region . EMBO. Journal 11:585–591
     [Google Scholar]
  31. Reitter J. N., Means R. E., Desrosiers R. C. 1998; A role for carbohydrates in immune evasion in AIDS. Nature Medicine 4:679–684
     [Google Scholar]
  32. Roben P., Moore J. P., Thali M., Sodroski J., Barbas C. F.III. 1994; Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Journal of Virology 68:4821–4828
     [Google Scholar]
  33. Scarlatti G. E., Albert J., Rossi P., Hodara V., Biraghi P., Muggiasca L., Fenyo E.-M. 1993; Mother-to-child transmission of human immunodeficiency virus type 1 – correlation with neutralising antibodies against primary isolates. Journal of Infectious Diseases 168:207–210
     [Google Scholar]
  34. Shotton C., Arnold C., Sattentau Q., Sodroski J., McKeating J. M. 1995; Identification and characterisation of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the HIV-1 envelope glycoprotein. Journal of Virology 69:222–230
     [Google Scholar]
  35. Srivastava I. K., Stamatatos L., Legg H., Kan E., Fong A., Coates S. R., Leung L., Wininger M., Donnolly J. L., Ulmer J. B., Barnett S. W. 2002; Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. Journal of Virology 76:2835–2847
     [Google Scholar]
  36. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J. P., Katinger H. 1996; Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology 70:1100–1108
     [Google Scholar]
  37. Von Gegerfelt A., Albert J., Morfeldt-Manson L., Broliden K., Fenyo E.-M. 1991; Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease. Virology 185:162–168
     [Google Scholar]
  38. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., Robinson J., Posner M., Sodroski J. 1993; Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. Journal of Virology 67:4557–4565
     [Google Scholar]
  39. Yang X., Florin L., Farzan M., Kolchinsky P., Kwong P. D., Sodroski J., Wyatt R. 2000; Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. Journal of Virology 74:4746–4754
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-11-2723
Loading
Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response
J. Gen. Virol. 83, 2723 (2002); https://doi.org/10.1099/0022-1317-83-11-2723
/content/journal/jgv/10.1099/0022-1317-83-11-2723
/content/journal/jgv/10.1099/0022-1317-83-11-2723
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error